LTRN | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 5%

Liquidity 50%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.64%

1 Month

-0.16%

3 Months

-20.28%

6 Months

-22.07%

1 Year

-23.78%

2 Year

-42.34%

Key data

Stock price

$3.11

P/E Ratio

0.00

DAY RANGE

$3.05 - $3.97

EPS

$0.00

52 WEEK RANGE

$2.98 - $11.99

52 WEEK CHANGE

-$21.68

MARKET CAP

44.028 M

YIELD

N/A

SHARES OUTSTANDING

10.765 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/06/2024

BETA

1.54

PUBLIC FLOAT

AVERAGE 10 VOLUME

$55,668

AVERAGE 30 VOLUME

$73,886

Company detail

CEO: Panna L. Sharma
Region: US
Website: lanternpharma.com
Employees: 20
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LTRN - Lantern Pharma Inc.